TMX-3013

Overview

TMX-3013 is a CDK inhibitor capable of inhibiting the activity of CDK1 , CDK2 , CDK4 , CDK5 , and CDK6 , with IC 50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be used as a target protein ligand , conjugated with the PROTAC linker and the CRBN ligand Thalidomide ( HY-14658 ) for the synthesis of PROTAC TMX-2138 ( HY-164906 ). TMX-3013 can also act as an effector ligand, binding to target proteins HaloTag or FKBP , and can be used in the synthesis of regulated induced proximity targeting chimeras (RIPTACs).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ligands for Target Protein for PROTAC | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-151071
• CAS No.: 2488761-18-6
• Molecular Formula: C17H14BrFN6O3S
• Molecular Weight: 481.30
• Purity: 98.02%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (10.39 mM); Clear solution
• Availability: In-stock

Source

Original product source